Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Medacta Group SA    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Medacta : announces a revision of the full year guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
12/05/2019 | 01:55pm EST

EQS Group-Ad-hoc: Medacta Group SA / Key word(s): Change in Forecast
Medacta Group SA announces a revision of the full year guidance

05-Dec-2019 / 19:48 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Press Release
2019 GUIDANCE REVISION

CASTEL SAN PIETRO, 5 December 2019 - Medacta Group SA announces a revision of the full year guidance.

The company continues to expand, achieving strong revenue growth well above the market growth rate while maintaining a high profitability level.

Following an unexpected weak demand in the US and in some minor markets covered by distributors, the overall growth rate in November was below expectations, 8% compared to 17% of the same period of last year. This performance changed the scenario of the year-end forecasted results. Accordingly, the year-end 2019 guidance is as follows:

- Revenue: reported growth in the range of 12-14%, equal to 10-12% on a constant currency basis (previously equal to 13-17%)

- Adjusted EBITDA: approximately 30% +/-1% (previously 32% +/-1%)

- Change in Net Working Capital: 5-7% of total revenue (maintained)

- CapEx: 12-15% of total revenue (previously 10-12%)

We expect that this revision on full year performance does not affect the mid-term performance.
Medacta is planning to report preliminary unaudited top-line figures on 21 January 2020 and full-year 2019 results on 6 April 2020.

Contact
Medacta Group SA
Corrado Farsetta, CFO
Phone: +41 91 696 60 60
investor.relations@medacta.ch

About Medacta:
Medacta is an international company specializing in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques for joint replacement, spine surgery, and sports medicine. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS") technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated "MySolutions" technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures.
 



End of ad hoc announcement
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 929805

 
End of Announcement EQS Group News Service

929805  05-Dec-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=929805&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MEDACTA GROUP SA
02/19MEDACTA GROUP SA : Interim award in microport case
EQ
01/23MEDACTA : Announces Several First-time Surgeries and CE Marking for Multiple Pro..
EQ
01/21MEDACTA : revenue up by 14%, with a strong revenue growth above the market in al..
EQ
2019MEDACTA : Receives FDA Clearance for MyShoulder Placement Guides
EQ
2019MEDACTA : announces a revision of the full year guidance
EQ
2019MEDACTA : Announces First U.S. Surgery with MectaScrew PEEK following FDA Cleara..
EQ
2019MEDACTA : Announces First Surgery with MectaLock PEEK in Australia
EQ
2019MEDACTA : publishes CSR Report and pays a Special 20 Year Anniversary Fidelity B..
EQ
2019MEDACTA : Receives CE Marking for the Lateralized Glenosphere
EQ
2019MEDACTA GROUP SA : 2019 Half-Year results
EQ
More news
Financials (EUR)
Sales 2019 309 M
EBIT 2019 59,1 M
Net income 2019 35,3 M
Debt 2019 142 M
Yield 2019 0,58%
P/E ratio 2019 43,7x
P/E ratio 2020 28,4x
EV / Sales2019 5,55x
EV / Sales2020 4,86x
Capitalization 1 571 M
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 74,28  €
Last Close Price 78,55  €
Spread / Highest target 6,68%
Spread / Average Target -5,44%
Spread / Lowest Target -15,1%
EPS Revisions
Managers
NameTitle
Francesco Siccardi Chief Executive Officer
Alberto Siccardi Chairman
Corrado Farsetta Chief Financial Officer
Maria Luisa Siccardi Tonolli Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDACTA GROUP SA14.92%1 705
MEDTRONIC PLC0.36%151 884
BAXTER INTERNATIONAL INC.10.82%47 313
HOYA CORPORATION-0.10%34 270
ZIMMER BIOMET HOLDINGS5.15%32 373
DEXCOM, INC.33.15%26 677